novo nordisk oral semaglutide brand name Wegovy Pill Becomes First GLP-1 Weight-Loss Drug Approved in U.S Oral GLP-1 receptor agonist Rybelsus
Description
Research shows that restoring GLP-1 signaling reduces activity in your brain's reward centers associated with food cravings, making high-calorie and ultra-processed foods feel less appealing
Link, C
Side effects at this dose are typically mild
Before and at the end of the study, the scientists assessed: body weight
In Phase 2b with human patients, the oral route was not confirmed
However, its equally important to be aware of potential side effects, such as stomach discomfort, nausea, and reduced vitamin B12 levels with long-term use
